Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab added to ezetimibe versus ezetimibe alone in statin-intolerant haemodialysis patients with hypercholesterolemia
2019-001491-11Phase 4Completed
- Sponsor
- IRCCS San Raffaele Pisana
- Start
- May 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab and ezetimibe in hypercholesterolemia and lipid metabolism disorder (2 arms), sponsored by IRCCS San Raffaele Pisana. Started May 2021; status: completed.
02
Drugs
evolocumabezetimibe
03
Conditions
hypercholesterolemialipid metabolism disorder
Beyond the preview
Go deeper on 2019-001491-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001491-11.